Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.

× No keyword cloud information.

16 in total

Review 1. Management of egfr tki-induced dermatologic adverse events.

Authors: B Melosky; N B Leighl; J Rothenstein; R Sangha; D Stewart; K Papp
Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677

2. Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study.

Authors: Cécile Charles; Darius Razavi; Catherine Bungener; Christine Mateus; Emilie Lanoy; Michèle Verschoore; Sarah Dauchy; Caroline Robert
Journal: Clin Drug Investig Date: 2016-03 Impact factor: 2.859

3. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer.

Authors: V Hirsh
Journal: Curr Oncol Date: 2011-06 Impact factor: 3.677

4. Unilateral onycholysis in a patient taking erlotinib (Tarceva).

Authors: Robert Stevenson; Ahmed El-Modir
Journal: BMJ Case Rep Date: 2011-08-11

Review 5. Hair disorders in patients with cancer.

Authors: Azael Freites-Martinez; Jerry Shapiro; Shari Goldfarb; Julie Nangia; Joaquin J Jimenez; Ralf Paus; Mario E Lacouture
Journal: J Am Acad Dermatol Date: 2018-04-14 Impact factor: 11.527

6. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.

Authors: Iris Amitay-Laish; Michael David; Salomon M Stemmer
Journal: Oncologist Date: 2010-08-13

7. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors: M Fakih; M Vincent
Journal: Curr Oncol Date: 2010-07 Impact factor: 3.677

8. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Authors: Durga S Borkar; Mario E Lacouture; Surendra Basti
Journal: Support Care Cancer Date: 2012-11-15 Impact factor: 3.603

9. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.

Authors: Howard A Burris; Charles W Taylor; Suzanne F Jones; Kevin M Koch; Melissa J Versola; Niki Arya; Ronald A Fleming; Deborah A Smith; Lini Pandite; Neil Spector; George Wilding
Journal: Clin Cancer Res Date: 2009-10-13 Impact factor: 12.531

10. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors: B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal: Curr Oncol Date: 2009-01 Impact factor: 3.677